FDA Whiplash on Moderna’s Flu Shot Is a Policy Problem, Not a Stock-Ticker Story

Washington has a particular talent: making raw power smell like disinfectant. Not the clean kind. More like copier toner and a midnight committee room realizing the public has started reading the footnotes. The binder snaps shut, and somebody clears a familiar phrase for reuse: standards.

This week the Food and Drug Administration did what institutions do when they stumble in public. It reversed course.

What the FDA changed, and why people notice

On February 18, 2026, after a formal back-and-forth, the FDA agreed to initiate review of Moderna’s application for a seasonal flu shot using mRNA technology, after previously refusing to even accept the filing. Moderna also revised its approach by age: it is now seeking full approval for adults ages 50 to 64, and accelerated approval for adults 65 and older, paired with a commitment to conduct an additional study in older adults. The FDA set a target decision date of August 5, 2026.

Just last week, the agency had issued a rare refusal-to-file letter. Translation: not simply “no,” but “we are not even opening the docket.” That kind of procedural lurch is where trust goes to die.

The substantive dispute (fine) vs the procedural whiplash (not fine)

The stated dispute was about trial design and what counts as an appropriate comparison, especially for seniors. Regulators argued the key study compared Moderna’s candidate to a standard-dose flu shot rather than the higher-dose shots often used for people 65 and older.

Reasonable people can debate comparators. That is what review is for. The problem is changing lanes without signaling, then calling it routine.

The Paine test

Does this expand liberty, or concentrate it in a few hands? When rules quietly tighten, then quietly loosen, “high standards” starts functioning less like a yardstick and more like a baton. Even if the motive is bureaucratic self-protection, the effect is the same: more dependence on whoever holds the microphone.

The Orwell check

Watch the euphemisms. If the agency believes seniors require a high-dose comparator, say it clearly, early, and publicly. Put it in guidance researchers can rely on before years of work and enrollment. And when the agency changes its mind, show the work.

The liberty ledger and the tradeoff

A review could eventually expand options for adults 50 and older. Options are freedom. But refusal-to-file cuts off the public process before it starts: fewer documents, fewer meetings, less scrutiny, more “trust us.” In public health, credibility does the heavy lifting downstream, shaping what employers require, what insurers cover, and what pharmacies stock.

Process is the compromise between faster innovation and safer proof. If the FDA wants high standards, good. Now deliver high explainability, too.